ISHLT 2025 | Early Clinical Insights on NyokAssist®

Boston, MA – April 28, 2025 

From April 27–30, 2025, the Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) convened in Boston, Massachusetts, bringing together global leaders in advanced heart and lung failure, mechanical circulatory support (MCS), and transplantation to share the latest developments in research, technology, and clinical practice.

Presentation of Early Clinical Data

During the scientific sessions, preliminary results from a prospective, multicenter clinical trial evaluating NyokAssist®were presented by  Dr. Rui Wang from Zhongshan Hospital (Fudan University) . NyokAssist® is a percutaneous ventricular assist device developed through close collaboration between clinicians and engineers. 

The study focuses on the use of NyokAssist® for patients undergoing high-risk cardiac interventions. Early findings suggest that percutaneous insertion was achieved safely, with smooth closure procedures. To date, favorable safety outcomes have been observed, including low complication rates and no major vascular complications reported across enrolled patients. The trial is ongoing.

NyokAssist®: 

NyokAssist® is a percutaneous ventricular assist device developed through close collaboration between clinicians and engineers, which has:

• 9 Fr insertion profile to minimize procedural trauma

• External motor design to reduce device costs and eliminate heat-related blood damage

The device's flexible outflow segment allows for smooth navigation across the aortic valve and minimizes interference with valve function during the cardiac cycle. It was awarded the U.S. FDA Breakthrough Device Designation and recognized as an Innovative Medical Device by the Chinese National Medical Products Administration (NMPA)

About ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a multidisciplinary organization committed to advancing research, education, and innovation in the treatment of patients with advanced heart and lung diseases. Since its founding in 1981, ISHLT has served as a leading platform for cardiologists, cardiac surgeons, pulmonologists, transplant specialists, and researchers to share breakthrough science, foster collaboration, and improve patient outcomes worldwide.